Enterocolitis due to Clostridium difficile is a symptomatic infection caused by the gram-positive, spore-forming, anaerobic bacillus Clostridium difficile (C. diff). This condition typically occurs when the healthy gut microbiota is disrupted, most often following the administration of broad-spectrum antibiotics, allowing C. difficile to colonize the colon and produce two primary exotoxins (Toxin A and Toxin B). These toxins trigger an inflammatory response in the intestinal mucosa, leading to a range of clinical presentations from mild antibiotic-associated diarrhea to severe, life-threatening complications such as pseudomembranous colitis, toxic megacolon, bowel perforation, and septic shock. In recent decades, the incidence and severity of C. diff infections have increased, partially due to the emergence of hypervirulent strains like NAP1/BI/027. Effective management includes discontinuation of the inciting antibiotic (if possible) and targeted therapy with oral vancomycin or fidaxomicin, or in recurrent cases, fecal microbiota transplantation (FMT).
Distinguish between initial and recurrent episodes using specific ICD-10-CM codes to ensure accurate severity capture. Documentation must clearly state if the patient has had a prior documented episode within the last 8 weeks or if this is a subsequent relapse to justify the recurrent code.
Example: Patient presents with watery diarrhea (10 episodes/day), abdominal cramping, and leukocytosis (WBC 18.2). This is the second episode of Clostridium difficile enterocolitis in 6 weeks, following a 10-day course of oral vancomycin. Diagnosis: Recurrent enterocolitis due to Clostridium difficile (A04.71). Plan: Initiate Fidaxomicin and evaluate for Bezlotoxumab infusion due to high risk of further relapse.
Billing Focus: Specificity of recurrence status (A04.71 vs. A04.72) determines the diagnosis code.
Document clinical markers of severity such as hypotension, fever, ileus, or significant leukocytosis. Clinical documentation of fulminant or severe C. difficile enterocolitis supports higher level Evaluation and Management (E/M) coding and accurately reflects the patient's risk profile.
Example: 74-year-old female with acute onset of severe abdominal distension, fever of 102.4F, and hypotension (BP 88/56). CT abdomen shows colonic wall thickening and thumbprinting. Labs reveal WBC 25,000 and Creatinine 2.1 (baseline 0.9). Impression: Fulminant Clostridium difficile enterocolitis with acute kidney injury and systemic inflammatory response. Management: IV Metronidazole plus high-dose oral Vancomycin via nasogastric tube.
Billing Focus: Documentation of systemic manifestations and organ dysfunction (e.g., AKI, SIRS) supports high-complexity MDM for E/M 99215 or 99223.
Clearly link the C. difficile infection to any associated complications such as toxic megacolon or perforation. Use 'due to' or 'secondary to' phrasing to establish a clinical causal relationship for coding purposes.
Example: Patient admitted for worsening abdominal pain and cessation of bowel movements. Imaging confirms toxic megacolon secondary to Clostridium difficile enterocolitis. General surgery consulted for possible subtotal colectomy. Diagnosis: Clostridium difficile enterocolitis (A04.72) with associated toxic megacolon (K58.2).
Billing Focus: Linking the infectious agent to the anatomical complication (megacolon) allows for specific secondary coding.
Identify and document the specific antibiotic or drug that preceded the infection if known. While not always required for the primary code, documenting 'drug-induced' status or 'adverse effect of antibiotics' provides a complete clinical picture.
Example: Acute Clostridium difficile enterocolitis following a 14-day course of Clindamycin for dental abscess. Patient presents with abdominal pain and mucus-streaked stools. Diagnosis: Enterocolitis due to Clostridium difficile (A04.72); Adverse effect of clindamycin, initial encounter (T36.3X5A).
Billing Focus: Including the T-code for adverse effects provides additional specificity regarding the etiology of the condition.
Specify the laboratory method used for confirmation (PCR vs. EIA) and whether the patient is a carrier or has active disease. Documentation should focus on the presence of symptoms (diarrhea) plus a positive toxin assay to validate the diagnosis.
Example: Patient reports 6 loose stools per day. Stool PCR positive for C. difficile toxin B gene; enzyme immunoassay (EIA) also positive for free toxin, confirming active Clostridium difficile enterocolitis. Not merely colonization. Diagnosis: Enterocolitis due to Clostridium difficile (A04.72).
Billing Focus: Clinical validation of laboratory results in the note prevents audits regarding 'colonization' vs 'active infection' status.
Typically used for management of uncomplicated C. diff requiring prescription changes and monitoring.
Used for patients with severe symptoms or recurrent C. diff with multiple comorbidities requiring complex decision making.
Appropriate for follow-up of a resolving infection with stable clinical status.
The standard diagnostic test used to confirm the presence of the organism in stool samples.
Used to confirm the presence of active toxin production, distinguishing infection from colonization.
Required procedure code for fecal microbiota transplantation (FMT) in recurrent C. diff cases.
Used to visualize pseudomembranes in severe or atypical presentations of C. diff.
Applied to patients admitted with fulminant C. diff, dehydration, or systemic sepsis.
Used specifically for Medicare and certain other payers for FMT procedures.
Relevant for the administration of Bezlotoxumab or IV Metronidazole.